Skip to main content
Toggle navigation
Login
Search
Home
iwCLL X / Twitter
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Browse by Category
Home
Browse by Category
Browse by Category
Type here to filter the list
Encore
2001 - Changes in immune cell numbers and profile during long-term zanubrutinib treatment in treatment-naïve and relapsed/refractory patients with chronic lymphocytic leukemia
Favorite
2002 - Final 7-year Follow Up and Retreatment Substudy Analysis of MURANO: Venetoclax-Rituximab-Treated Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
Favorite
2003 - Genomic Evolution and Resistance to Pirtobrutinib in Covalent BTK-Inhibitor Pre-treated Chronic Lymphocytic Leukemia Patients: Results from the Phase I/II BRUIN Study
Favorite
2004 - Lisocabtagene maraleucel (liso-cel) in R/R chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): primary analysis of TRANSCEND CLL 004
Favorite
2005 - A phase 1 study evaluating PRT2527, a potent and highly selective CDK9 inhibitor, in patients with select relapsed/refractory B-cell malignancies
Favorite
2006 - Impact of nucleotide metabolism on CLL B-cell pathobiology and CLL disease progression
Favorite
2007 - Real-World Duration of Venetoclax Treatment for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Favorite
2008 - BRUIN CLL-314: A phase 3, open-label, randomized study of pirtobrutinib versus ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (trial in progress)
Favorite
2009 - A phase 2 study of zanubrutinib in previously treated B-cell malignancies intolerant to ibrutinib and/or acalabrutinib: preliminary results for patients with CLL/SLL
Favorite
2010 - Zanubrutinib vs bendamustine + rituximab (BR) in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma: extended follow-up of the SEQUOIA study
Favorite
2011 - Long-term Safety with ≥12 Months of Pirtobrutinib in Relapsed/Refractory (R/R) B-Cell Malignancies
Favorite
2012 - Matching-Adjusted Indirect Comparison of Pirtobrutinib vs Venetoclax Continuous Monotherapy in Patients with Relapsed/Refractory CLL Previously Treated with a Covalent BTK Inhibitor
Favorite
2013 - Zanubrutinib vs ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): impact on health-related quality of life (HRQoL)
Favorite
2014 - Characterization of the safety/tolerability profile of zanubrutinib and comparison with the profile of ibrutinib in patients with B-cell malignancies: post hoc analysis of a large clinical trial safety database
Favorite
2015 - VENETOCLAX RETREATMENT AFTER MRD-GUIDED VENETOCLAX +/- IBRUTINIB: THE IMPROVE STUDY COHORT
Favorite
2016 - Long-term follow-up of multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated patients with chronic lymphocytic leukemia: Impact of early MRD kinetics on posttreatment outcomes
Favorite
2017 - Venetoclax-Obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized CLL14 study
Favorite
2018 - Over-Time Monitoring of CXCR4dim/CD5bright Proliferative Fraction Anticipates Relapse In Ibrutinib-Treated CLL : a reservoir for BTK mutations?
Favorite
2019 - Covalent menin inhibitor, BMF-219, impacts key gene signatures and molecular pathways in Chronic Lymphocytic Leukemia patient-derived models
Favorite
2020 - NX-5948 and NX-2127 potently degrade a broad array of clinically-relevant BTK mutants that display resistance to inhibitors and other BTK degraders
Favorite
2021 - Health-related quality of life in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma treated with liso-cel in TRANSCEND CLL 004
Favorite
2022 - Prolonged treatment with ibrutinib modulates phenotypic and functional features of immune cell compartments in chronic lymphocytic leukemia
Favorite
2023 - Del8p and TNFRSF10B loss are associated with a poor prognosis and resistance to fludarabine in chronic lymphocytic leukemia
Favorite
2024 - Phase 1/2 Study of Zilovertamab and Ibrutinib: Durable responses suggest a novel mechanism for synthetic lethality in TP53 aberrant disease.
Favorite
2025 - Real-world dosing patterns and outcomes in patients with chronic lymphocytic leukemia patients with or without dose adjustment of first-line ibrutinib
Favorite
2026 - Real-world treatment outcomes in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who were treated with first-line single-agent ibrutinib vs chemoimmunotherapy
Favorite
2027 - Real-world assessment of dosing patterns and treatment outcomes in patients with chronic lymphocytic leukemia who initiated first-line single-agent ibrutinib in an integrated claims-based database
Favorite
2028 - Genomic Alterations and Outcomes with Fixed-duration Ibrutinib + Venetoclax: Results from the Phase 3 GLOW Study in Patients with Previously Untreated CLL
Favorite
General Abstract
1001 - Identification of novel targets that upregulate CD20 expression in rituximab-resistant cells with the use of genome-wide CRISPR screening
Favorite
1002 - m6A-modified circTET2 interacting with HNRNPC regulates fatty acid oxidation to promote the proliferation of chronic lymphocytic leukemia
Favorite
1003 - Refining the phenotypic and functional intraclonal complexity in chronic lymphocytic leukemia B cells uncovers a discrepancy between surface membrane IG levels and time since birth supporting the requirement for multifactorial activation and different subclonal sensitivities to treatment.
Favorite
1004 - The PKCβ inhibitor MS-553 displays preclinical efficacy in BTK inhibitor resistant Chronic Lymphocytic Leukemia
Favorite
1005 - Toll-like receptor 9 signalling in CLL: a resistance mechanism to B-cell receptor-targeted treatments, and a potential tool for therapeutic stratification.
Favorite
1006 - Transcription factor FoxO1 Mediates Adaptive Increase in Akt Activity and Cell Survival During BCR Inhibitor Therapy in CLL
Favorite
1007 - XPO1 mutations identify early stage CLL characterized by shorter time to first treatment and enhanced BCR signaling
Favorite
1008 - XPO1 inhibitor Selinexor induces heme oxygenase-1 mediated p53-dependent ferroptosis in chronic lymphocytic leukemia
Favorite
1009 - IMMUNOGENETICS AND ANTIGEN REACTIVITY PROFILING CONTRIBUTE TO UNRAVELLING THE ONTOGENY OF CLL STEREOTYPED SUBSET #4
Favorite
1010 - The interplay between BcR signaling and the p53 pathway upon DNA damage in primary CLL cells
Favorite
1011 - In-depth molecular analysis using a multi-gene lymphoma NGS panel in lymphomas with lymphoplasmacytic differentiation may provide more precise diagnosis, differentiation of entities and may optimize rational treatment allocations
Favorite
1012 - High-dimensional Single-cell Characterisation of the Chronic Lymphocytic Leukaemia Tumour Microenvironment using Imaging Mass Cytometry
Favorite
1013 - The role of artificial intelligence in differential diagnosis and prognostic significance of Small B-cell lymphoma
Favorite
1014 - Clonal architecture and single-cell transcriptome landscape in Richter’s syndrome
Favorite
1015 - Coupled effect of a miR-155 deficiency and hypoxia conditions leads to the upregulation of SLC2A1 (GLUT1), SLC2A3 (GLUT3) and EGLN1 genes in the leukemic B-cells
Favorite
1016 - DEFACTINIB AFFECTS CHRONIC LYMPHOCYTIC LEUKEMIA CELL SURVIVAL WITH ADDITIVE EFFECT IN COMBINATION WITH BTK INHIBITORS
Favorite
1017 - NOTCH pathway mutation contributes to inferior prognosis in HBV-infected chronic lymphocytic leukemia
Favorite
1018 - Fatty Acid Metabolism Fingerprints Predict Prognosis and Regulate Immunophenotype in Chronic Lymphocytic Leukemia
Favorite
1019 - Chemokine receptor and adhesion molecule profile on B-cell chronic lymphocytic leukemia (B-CLL) lymphocytes in different lymphoid compartments and changes during BTK inhibitor therapy
Favorite
1020 - The mechanical properties of CLL cells are linked to the actin cytoskeleton and are target of BTK inhibitors
Favorite
1021 - Transcriptional correlation analysis of the CD180/MD-1 complex and toll-like receptors and signaling lymphocyte activation family receptors in chronic lymphocytic leukemia.
Favorite
1022 - FOXO4 is required for the promotion of CLL growth and survival
Favorite
1023 - Targeting NF-κB-inducing kinase (NIK) in chronic lymphocytic leukaemia
Favorite
1024 - Impaired mitochondrial metabolism drives T-cell dysfunction in chronic lymphocytic leukemia
Favorite
1025 - Curcumin enhances ibrutinib induced killing effect against TP53-mutated Chronic Lymphocytic Leukemia cells in vitro
Favorite
1026 - Targeting the pro-inflammatory protein S100-A9 in Chronic Lymphocytic Leukemia
Favorite
1027 - B cell receptor-mediated signals modulate rapid FOXO1 upregulation in chronic lymphocytic leukaemia: a role for deubiquitinate proteins?
Favorite
1028 - Peripheral Blood CXCR4hiCD5hi Chronic Lymphocytic Leukaemia Cells are Primed for Returning to the Lymph Nodes for further Activation and Proliferation
Favorite
1029 - Deubiquitinase PSMD14 Promotes Progression of Chronic Lymphocytic Leukemia by Stabilizing CSDE1
Favorite
1030 - Immunophenotypic Characterization of Richter Syndrome Diffuse Large B-Cell Lymphoma Type and Comparison with the Original Chronic Lymphocytic Leukemia
Favorite
1031 - Sex Bias in Mutational Landscape of Chronic Lymphocytic Leukemia: Analysis of Clinical Sequencing Data
Favorite
1032 - Clonal Space Assessment in Chronic Lymphocytic Leukemia Using an Unbiased NGS Approach
Favorite
1033 - Single-Cell Transcriptome Profiling Reveals Neoplastic Effects of Exosomal S100A4 in Chronic Lymphocytic Leukemia
Favorite
1034 - Venetoclax resistance induced by activated T cells can be counteracted by sphingosine kinase inhibitors in chronic lymphocytic leukemia
Favorite
1035 - ENPP2 mediates lipid metabolism and tumorigenesis in chronic lymphocytic leukemia through AMPK signaling pathway
Favorite
1036 - Chronic lymphocytic leukemia extracellular vesicles induce the differentiation of monocytes into nurse-like cells
Favorite
1037 - Activation of S100-A9/EMMPRIN axis triggers survival/proliferation pathways in leukemic cells. A novel target for chronic lymphocytic leukemia
Favorite
1038 - Inhibition of G protein-coupled receptor kinase 2 (GRK2) as a strategy to modulate leukemic cell homing and activation in CLL
Favorite
1039 - The proto-oncogene TCL1A deregulates cell cycle and genomic stability in CLL
Favorite
1040 - Exploring the impact of germline ATM mutations in cancer susceptibility and inheritance in chronic lymphocytic leukemia
Favorite
1041 - Anti-FcμR Antibody Drug Conjugate as a Potential Therapeutic Agent for the Treatment of Chronic Lymphocytic Leukemia
Favorite
1042 - LOSS OF IκBε ACCELERATES DISEASE DEVELOPMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA
Favorite
1043 - Regulation of the NF-kB pathway by NEDDylation in chronic lymphocytic leukemia: Beyond IkB
Favorite
1044 - T cells from chronic lymphocytic leukemia patients are not exhausted but show signs of senescence, providing alternative clues for improvement
Favorite
1045 - LYN kinase programs stromal fibroblasts to facilitate leukemic survival via regulation of c-JUN and THBS1
Favorite
1046 - Unveiling the Role of Siglec-6 in Regulating B Cell Functions: Implications for Chronic Lymphocytic Leukemia Therapeutics
Favorite
1047 - Prognosis Analysis and Validation of Fatty Acid Metabolism-Related Signature in Chronic lymphocytic leukemia
Favorite
1048 - SH2-Flow: A Multiplex Single Cell Phosphotyrosine Profiling Tool for B-cell Malignancies
Favorite
1049 - Impact of T-cell co-stimulatory molecule CLECL1 expressing CLL cells on CLL disease progression and transformation to Richter's syndrome
Favorite
1050 - NX-2127 and NX-5948, two clinical stage cereblon-recruiting BTK degraders, facilitate T-cell functionality in CLL
Favorite
1051 - Increased susceptibility to Streptococcus pneumoniae pulmonary infection in the Eµ-TCL1 adoptive transfer mouse model of CLL
Favorite
1052 - PI3K inhibitor-resistant B-cell lymphomas show distinct functional phenotypes characterized by sensitivity to Bcl-2- or proteasome-inhibition
Favorite
1053 - Explainable Machine Learning to Identify Chronic Lymphocytic Leukemia Based on Gut Microbiome Data
Favorite
1054 - The RNA-binding protein Musashi2 is regulated by NOTCH1/KLF4 pathway and support tumor survival keeping CLL cells in proliferative niches during disease progression
Favorite
1055 - Single-cell transcriptomic analysis of CLL cells at ibrutinib plus venetoclax relapse and targeting using BCL-2/BCL-xL PROTACs PZ18753b and WH25244
Favorite
1056 - LYN kinase and its regulator CSK as key players in CLL-supporting macrophages
Favorite
1057 - Combining CD19 CAR T cells with T cell-engaging bispecific antibody treatment enhances efficacy in murine models of CLL and ex vivo patient cultures
Favorite
1058 - T-cell Transcriptional and Mitochondrial Fitness Reprogramming in CLL Using PI3Kδ Inhibitors
Favorite
1059 - Lisaftoclax (APG-2575) is a novel BCL-2 inhibitor with robust antitumor activity in preclinical models of hematologic malignancy
Favorite
1101 - Association between hypertension and overall survival in chronic lymphocytic leukemia
Favorite
1102 - Integrating Multi-Omics to Reveal the Heterogeneous Clonal Evolutionary Characteristics in CLL Patients with Zanubrutinib Resistance
Favorite
1103 - Single-cell RNA sequencing Reveals the Spatial Heterogeneity in BTKi-Resistant Richter Transformation Patients
Favorite
1104 - Non-Hematological Autoimmune Disorders are frequent in CLL, but are they clinically related? Data from a Single-center Real-Life Cohort
Favorite
1105 - SAFETY AND EFFECTIVENESS IN CLL PATIENTS TREATED WITH VENETOCLAX MONOTHERAPY IN AUSTRIA, GERMANY, AND SWITZERLAND - LONG TERM FOLLOW UP DATA
Favorite
1106 - Clinical Relevance of the Recommended Intensive Laboratory Monitoring during the Standard Ramp-up at Time of Venetoclax Initiation for CLL: A Real-World Experience
Favorite
1107 - Mechanisms of differential response to BTKi targeted therapy in patients with chronic lymphocytic leukemia
Favorite
1108 - Uncovering the immune-related challenges facing people with chronic lymphocytic leukaemia
Favorite
1109 - Real world treatment patterns, reasons for discontinuation, and survival outcomes among patients with chronic lymphocytic leukemia/ small lymphocytic lymphoma (CLL/SLL) receiving second or later lines of therapy in a contemporary population treated in the United States
Favorite
1110 - Systematic literature review (SLR) of treatments and outcomes in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) previously treated with Bruton tyrosine kinase inhibitors (BTKi) and venetoclax
Favorite
1111 - Immune-profiling of ibrutinib-treated CLL patients revealed TMBIM6 as a potential target for CLL and its high expression as an independent variable associated with poor prognosis
Favorite
1112 - Immunophenotyping of Chronic Lymphocytic Leukemia in Yemen.
Favorite
1113 - Pericardial effusion in patients with chronic lymphocytic leukemia treated with Bruton's tyrosine kinase inhibitors
Favorite
1114 - Pharmacokinetics of idelalisib and outcomes
Favorite
1115 - Venetoclax Consolidation after BTKi Based Therapy for Patients with CLL
Favorite
1116 - SAFETY PROFILE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA UNDERGOING TREATMENT WITH 1ST AND 2ND GENERATION BRUTON TYROSINE KINASE INHIBITORS: MULTICENTRIC REAL-WORLD EXPERIENCE
Favorite
1117 - EVOLUTION IN THE FRONTLINE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: EXPERIENCE FROM ONE EUROPEAN CENTER
Favorite
1118 - Similar discriminatory values of IPS-E, AIPSE, and CR0 scores predicting time to first treatment in a large series of unselected patients with early-stage CLL
Favorite
1119 - Treatment Strategies and Outcomes for Double Refractory chronic lymphocytic leukemia; A single center experience
Favorite
1120 - Single-cell RNA-seq analysis reveals distinct tumor and immunosuppressive T cell phenotypes in CLL patients treated with ibrutinib.
Favorite
1121 - Safety of concomitant delivery of radiotherapy for second primary malignancy in patients with chronic lymphocytic leukemia treated with continuous novel agents
Favorite
1122 - Treatment Patterns and Outcomes of Patients with TP53-Mutated Chronic Lymphocytic Leukemia
Favorite
1123 - Anti-CD19 Chimeric Antigen Receptor T-cell therapy for Richter’s Transformation: A Multicenter Retrospective Study
Favorite
1124 - Efficacy and toxicity of ibrutinib in CLL - Croatian experience. A non-interventional, real world study of KroHem
Favorite
1125 - Frequent monitoring in chronic lymphocytic leukemia clinical trials: what is the true value?
Favorite
1126 - Significance of sIL-2R and LD in predicting time to first treatment in Japanese CLL patients with early asymptomatic disease.
Favorite
1127 - Real-world treatment patterns, discontinuation and clinical outcomes in patients with B-cell lymphoproliferative diseases treated with BTK inhibitors in China
Favorite
1128 - Single-center study of COVID-19 infection in patients with chronic lymphocytic leukemia
Favorite
1129 - Incidence and clinical correlates of non-immune cytopenia at diagnosis of chronic lymphocytic leukemia
Favorite
1130 - Vertebral fractures in patients with B-cell chronic lymphocytic leukemia before and after ibrutinib treatment
Favorite
1131 - Performance of a novel 8-color flow cytometry panel in the detection of minimal residual disease assessment of chronic lymphocytic leukemia
Favorite
1132 - Very low COVID mortality and hospitalization rates in CLL and MBL with repeated vaccination to maximum antibody response
Favorite
1133 - COVID-19 infection in chronic lymphocytic leukemia (CLL) patients treated with venetoclax: a Danish single-center experience
Favorite
1134 - High deletion burden identified by whole genome sequencing is associated with enhanced risk in del17p CLL patients
Favorite
1135 - Predictive modeling of treatment outcomes in chronic lymphocytic leukemia based on functional profiles at baseline
Favorite
1136 - Serum Monoclonal Immunoglobulin Predicts Inferior Prognosis in Patients Treated for Chronic Lymphocytic Leukemia
Favorite
1137 - Efficacy of Immune Checkpoint Inhibitors for the Treatment of Advanced Melanoma (AM) in Patients with Concomitant Chronic Lymphocytic Leukemia (CLL)
Favorite
1138 - Low dose rituximab efficiently clears circulating CLL cells and maintains sensitivity to antibody dependent cellular cytotoxicity (ADCP)
Favorite
1139 - Initial anti-CD20 monoclonal antibody therapy in CLL quickly induces cytokine release syndrome with first dose infusion reaction correlating only with high IL-6, IL-8 and IP-10
Favorite
1140 - Pregnancy course of 10 women diagnosed with Chronic Lymphocytic Leukemia
Favorite
1141 - Reduced predictive value of elevated Beta-2-microglobulin plasma levels on time to first treatment in newly diagnosed CLL patients with compromised kidney function
Favorite
1142 - Treatment of symptomatic paraneoplastic fluidothorax in CLL with novel agents: a single-center case series.
Favorite
1143 - The Economic Benefits of Time Off Treatment: Real-World HRU, Costs, and Subsequent Treatment with Fixed Duration Venetoclax among Patients with Chronic Lymphocytic Leukemia
Favorite
1144 - Patients with unmutated IgHV_1-69; 1-02; 3-30; 4-39 and high expression of AID enzyme need earlier treatment.
Favorite
1145 - The role of 18F-FDG PET-CT in Richter Transformation and accelerated CLL
Favorite
1146 - Implementing the data-driven CLL-TIM algorithm into an EPIC-based EHR: proof of concept for automated decision support models
Favorite
1147 - Global Perspectives through multi stakeholder mapping of lived experience with CLL – insights to improve equity, services, and unmet need
Favorite
1148 - Time to treatment initiation in 17p-deleted Chronic Lymphocytic Leukemia has no influence on overall survival
Favorite
1149 - Ibrutinib induces cardiac arrhythmia by targeting CaV1.2 calcium channel
Favorite
1150 - Past informs the future: outcomes post allogeneic stem cell transplantation in high risk chronic lymphocytic leukaemia (CLL)
Favorite
1151 - The Impact of BTK Inhibitors on COVID-19 Outcomes in Patients with Chronic Lymphocytic Leukemia: A real-world study in the Omicron wave
Favorite
1152 - Optical genome mapping and fluorescence in situ hybridization is the best combination to identify genomic complexity and TP53 deletions in CLL patients
Favorite
1153 - SWITCHING FROM COVALENT BTKI TO BCL2i IS ASSOCIATED WITH IMPROVED CLINICAL OUTCOMES COMPARED TO SWITCHING TO A DIFFERENT COVALENT BTKI IN PATIENTS WITH CLL/SLL TREATED IN THE REAL-WORLD SETTING
Favorite
1154 - Impaired long-term antibody persistence after primary immunization with pneumococcal vaccines in patients with chronic lymphocytic leukemia compared to immunocompetent controls
Favorite
1155 - Loss of AID exacerbates the malignant progression of CLL
Favorite
1156 - Real-world Effectiveness and Safety of Tixagevimab/Cilgavimab Lower Dosage Regimen in Pre-Exposure Prophylaxis in Patients Undergoing Treatment for Chronic Lymphocytic Leukemia
Favorite
1157 - Significance of TP53 aberrations in context of other pathogenic sequence variants in patients with chronic lymphocytic leukemia in the era of targeted therapy
Favorite
1158 - A retrospective study evaluating the sequence of BTKi and venetoclax, with a focus on toxicity
Favorite
1160 - Clinical outcomes in patients with chronic lymphocytic leukemia (CLL) treated with venetoclax-based regimens
Favorite
1161 -
ZMYM3
Mutations Dysregulate Histone Acetylation and Impact the Outcome Of Chronic Lymphocytic Leukemia Patients
Favorite
1162 - Time-limited venetoclax-rituximab is effective for patients with Bruton tyrosine kinase exposed chronic lymphocytic leukaemia, but durable treatment-free remissions are uncommon
Favorite
1163 - Sensitive monitoring of sequential targeted therapy resistance in relapsed/therapy refractory chronic lymphocytic leukemia
Favorite
1164 - Mutations and translocations associated with venetoclax resistance in chronic lymphocytic leukemia (CLL)
Favorite
1201 - Impact of COVID-19 in patients with Chronic Lymphocytic Leukemia treated with venetoclax: a possible role of the association to anti-CD20 antibody? A multicentre SEIFEM study.
Favorite
1202 - T cell type abundance and gene expression patterns in the context of clinical progression of treatment-naïve CLL/MBL patients from the OxPLoreD study
Favorite
1203 - Chronic obstructive pulmonary disease and previous infections have impact on infectious complications in patients with Chronic Lymphocytic Leukemia treated with venetoclax: a multicentre SEIFEM study.
Favorite
1204 - Real-World Characteristics and Outcomes of Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Long-Term Ibrutinib: Results From the Prospective, Observational informCLL Registry
Favorite
1205 - Rituximab Maintenance after Chemoimmunotherapy Induction in 1st and 2nd Line Improves Progression Free Survival: Long Term Follow up of the International Randomized AGMT-CLL8/a Mabtenance Trial
Favorite
1206 - First-in-human open-label study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor, in patients with relapsed/refractory chronic lymphocytic leukemia and other hematologic malignancies
Favorite
1207 - A matching-adjusted indirect comparison of ELEVATE-TN versus SEQUOIA: acalabrutinib with and without obinutuzumab versus zanubrutinib in treatment-naïve chronic lymphocytic leukemia
Favorite
1208 - The HEALTH4CLL study: optimization of behavioral interventions for patients with chronic lymphocytic leukemia
Favorite
1209 - Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: A prospective real-world study in Chinese cohort
Favorite
1210 - A Phase II study of intermittent duvelisib dosing in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Favorite
1211 - Venetoclax as an Alternative and Effective Treatment in Central Nervous System Involvement of Chronic Lymphocytic Leukemia: Monocentric Experience
Favorite
1212 - Targeted agents in chronic lymphocytic leukemia (CLL): Data on outcomes and subsequent therapies of patients observed within the German CLL Study Group (GCLLSG) registry
Favorite
1213 - An examination of health literacy amongst patients with Chronic Lymphocytic Leukemia- A study from The Lymphoma Coalition Global Patient Survey 2022.
Favorite
1214 - An Investigation into the Differences between Western and Chinese population with Chronic Lymphocytic Leukemia
Favorite
1215 - Unveiling the Spectrum of Genetic Alterations in Relapsed/Refractory CLL Patients on Targeted Inhibitors: A Prospective Unicentric Study
Favorite
1216 - Characterizing Specificities of Chronic Lymphoid Leukemia Harboring a BCL2 Rearrangement, an update from the FILO group
Favorite
1217 - Evolution of natural history and prolongation of overall survival in patients with chronic lymphocytic leukemia: analysis of a long-term follow-up of an unselected cohort in the Hradec Králové district, Czech Republic.
Favorite
1218 - Lenalidomide Consolidation Improves Progression Free Survival in Patients with Chronic Lymphocytic Leukemia Following Initial FCR Chemotherapy - Final Analysis of CLL6 Residuum Study of the Australian Leukaemia and Lymphoma Group (ALLG) and the French Innovative Leukemia Organization (FILO)
Favorite
1219 - The evolution of treatments and outcome of patients with chronic lymphocytic leukemia treated at Fondazione Policlinico Universitario Agostino Gemelli IRCCS: a monocentric experience of the Last 30 Years.
Favorite
1220 - Longitudinal review of cardiac events with acalabrutinib in the treatment of chronic lymphocytic leukemia (CLL) using data from 3 phase 3 randomized controlled trials (RCTs)
Favorite
1221 - Occurrence and Evolution of Autoimmune Cytopenias in Chronic Lymphocytic Leukemia Patients treated with Venetoclax: a study of the French Innovative Leukemia Organization (FILO).
Favorite
1222 - KINETICS OF LYMPHOCYTOSIS DURING BTK COVALENT INHIBITORS IN TREATMENT NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS. AN ITALIAN MULTICENTER EXPERIENCE OF REAL LIFE.
Favorite
1223 - Anti-CD19 CAR T-cell therapy for patients with Richter syndrome: A LYSA Study from the DESCAR-T Registry
Favorite
1224 - Incidence of arrhythmia in chronic lymphocytic leukemia (CLL) patients treated with ibrutinib: a real-world retrospective analysis from two Italian centers.
Favorite
1225 - Real-world evidence on venetoclax in chronic lymphocytic leukemia: The KROHEM (Croatian cooperative group for hematological diseases) experience
Favorite
1226 - Outcomes of Tixagevimab/cilgavimab pre-exposure prophylaxis in Chronic lymphocytic leukemia patients- a single center experience
Favorite
1227 - Concomitant use of venetoclax 100 mg and ketoconazole to treat CLL in a public center in Brazil
Favorite
1228 - Single center report on cohort of patients relapsed on Bruton Tyrosine Kinase inhibitors (BTKi)
Favorite
1229 - A Study of Frontline Therapy in Adults Aged 80+ Years with Chronic Lymphocytic Leukemia (CLL)
Favorite
Late-Breaking General Abstract
4001 - Chronic lymphocytic leukemia patient-derived xenografts recapitulate clonal evolution to Richter transformation
Favorite
4002 - Longitudinal CITE-Seq analyses of the peripheral blood identify transcriptomic signatures associated with progression and transformation under targeted therapy
Favorite
4003 - VENETOCLAX TREATMENT OF REFRACTORY ITP IN CLL
Favorite
4004 - Tracking CLL cells with mutation in the TP53 gene using scRNAseq in relapsed/refractory patients
Favorite
4005 - STop and Restart Acalabrutinib In fRail Patients With Previously Untreated Chronic Lymphocytic Leukemia (STAIR): a randomized phase 2 study from the FILO-CLL group
Favorite
Trials In Progress
3001 - Sequencing of circulating tumour DNA reveals additional driver mutations in Richter Transformation
Favorite
3002 - Zanubrutinib and venetoclax as initial therapy for CLL with obinutuzumab triplet consolidation in patients with minimal residual disease positivity (BruVenG)
Favorite
3003 - COVALENT-101: Phase I Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL (NCT05153330)
Favorite
3004 - A Phase 2 Study of Minimal Residual Disease-Guided, Time-Limited, First-Line Therapy of Chronic Lymphocytic Leukemia with Pirtobrutinib and Venetoclax (MIRACLE)
Favorite
3005 - BRUIN CLL-322: A phase 3 open-label, randomized study of fixed duration pirtobrutinib plus venetoclax and rituximab versus venetoclax and rituximab in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (trial in progress)
Favorite
3006 - High-risk International Prognostic Score for early asymptomatic CLL (IPS-E) identifies chronic lymphocytic leukaemia at risk of progression to treatment in the OXPLORED study, a prospective observational study for early lymphoproliferative disease
Favorite
3007 - Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab (VO) versus Delayed Therapy with VO in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study (SWOG S1925; NCT#04269902)
Favorite
3008 - An ongoing first-in-human phase 1 trial of NX-5948, an oral Bruton’s tyrosine kinase (BTK) degrader, in patients with relapsed/refractory B cell malignancies, including chronic lymphocytic leukemia (CLL)
Favorite
3009 - Orelabrutinib combined with bendamustine and obinutuzumab as the first-line treatment for chronic lymphocytic leukemia/small lymphocytic leukemia: a phase II multicenter exploratory study
Favorite
